iShares U.S. Pharmaceuticals ETF (IHE)
| Assets | $599.85M |
| Expense Ratio | 0.39% |
| PE Ratio | 22.48 |
| Shares Out | 9.15M |
| Dividend (ttm) | $1.06 |
| Dividend Yield | 1.62% |
| Ex-Dividend Date | Sep 25, 2024 |
| Payout Ratio | 36.66% |
| 1-Year Return | +7.76% |
| Volume | 53,190 |
| Open | 65.88 |
| Previous Close | 65.15 |
| Day's Range | 65.58 - 66.47 |
| 52-Week Low | 60.60 |
| 52-Week High | 72.94 |
| Beta | 0.65 |
| Holdings | 42 |
| Inception Date | May 1, 2006 |
About IHE
Fund Home PageThe iShares U.S. Pharmaceuticals ETF (IHE) is an exchange-traded fund that is based on the DJ US Select / Pharmaceutical index. The fund tracks a broad-based, cap-weighted index of US pharmaceutical companies. IHE was launched on May 1, 2006 and is issued by BlackRock.
Top 10 Holdings
77.02% of assets| Name | Symbol | Weight |
|---|---|---|
| Johnson & Johnson | JNJ | 21.09% |
| Eli Lilly and Company | LLY | 20.07% |
| Bristol-Myers Squibb Company | BMY | 5.63% |
| Viatris Inc. | VTRS | 5.27% |
| Catalent, Inc. | CTLT | 4.75% |
| Zoetis Inc. | ZTS | 4.27% |
| Pfizer Inc. | PFE | 4.23% |
| Merck & Co., Inc. | MRK | 4.14% |
| Royalty Pharma plc | RPRX | 4.03% |
| Intra-Cellular Therapies, Inc. | ITCI | 3.53% |
Dividends
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Sep 25, 2024 | $0.359 | Sep 30, 2024 |
| Jun 11, 2024 | $0.294 | Jun 17, 2024 |
| Mar 21, 2024 | $0.275 | Mar 27, 2024 |
| Dec 20, 2023 | $0.13467 | Dec 27, 2023 |
| Sep 26, 2023 | $0.30067 | Oct 2, 2023 |
| Jun 7, 2023 | $0.19667 | Jun 13, 2023 |
News
IHE Contraction Is Not Justified By Fundamental Data
iShares U.S. Pharmaceuticals ETF is a pharmaceutical ETF offered by iShares, featuring an expense ratio of 0.39% and over $500 million in assets under management. In Q3, the healthcare sector reported...
IHE: Significant Growth Ahead, But Valuation Not Cheap (Rating Downgrade)
IHE invests in large-cap U.S. pharmaceutical stocks with solid long-term growth outlook but high concentration risk. IHE's fund price has been steady with a positive trend in 2024, but its elevated va...
Why investor appetite for commodity funds picked up despite ETF flows broadly seeing ‘pretty big drop' in April
Hello! This week's ETF Wrap digs into the slump in ETF flows in April and investor positioning around commodities as inflation worries persist.
This weight-loss ETF has performed well in its first five months. How does it compare with cheaper alternatives?
A new exchange-traded fund needs an edge to attract investors. This might be its industry focus — a tall order in a crowded market with ETFs covering just about any industry you can imagine.
New ETF invested in Ozempic maker and exposed to other obesity drugs falls in first day of trade
A new ETF hit the market Tuesday, creating buzz for its exposure to popular weight-loss drugs, while expanding the roster of thematic ETFs available for investors willing to pay up for stock-picking p...
IHE: You Better Like Eli Lilly And Johnson & Johnson To Buy This
The iShares U.S. Pharmaceuticals ETF provides targeted exposure to the U.S. pharmaceutical industry but has a highly concentrated portfolio. The IHE ETF's top five holdings, including Eli Lilly and Jo...
IHE: A Highly Concentrated Portfolio Is Able To Generate Growth Over The Long Run
iShares U.S. Pharmaceuticals ETF invests almost 80 percent of its assets in its top 10 holdings, and 48.5 percent in just two companies: JNJ and LLY. IHE didn't generate strong or decent yield, but pr...
IHE: Pharmaceutical Stocks Are Cheap And Offer High Long-Term Returns
IHE invests in U.S. pharmaceutical stocks. Based on consensus forward earnings growth estimates, IHE looks undervalued.
IHE: A Top-Heavy Pharma ETF That's More Average Than Outstanding
IHE tracks the Dow Jones U.S. Select Pharmaceuticals Total Return Index, which invests solely in U.S. pharmaceutical companies. The fund is top-heavy, investing around 40% in just two companies: Johns...
What The Inflation Reduction Act Means For Drug Prices
The recently enacted Inflation Reduction Act looks to rein in prescription drug prices and could impact the pharma industry's long-term financial performance. The legislation caps out-of-pocket costs ...
Biotech Innovations Remain At Forefront
The first quarter of 2021 was challenging for the biotechnology industry, as the selloff in March represented a sharp reversal from record highs in February. While the sector has remained relatively r...
Moving Beyond COVID In Biopharma
Just over one year after COVID-19 disrupted our lives, we are now getting to the point where multiple vaccine options are nearly ubiquitous for those in the United States. Per the CDC, as of April 12,...
Healthcare: A Wide Choice Of Large And Well-Established Companies
The advantage for dividend investors in this sector is the wide choice of large and well-established companies. AbbVie is a drug company with strong exposure to the immunology and the oncology markets...
Best Pharmaceutical ETFs for Q1 2021
The best pharmaceutical ETFs for Q1 2021 are KURE, XPH, and IHE.
iShares U.S. Pharmaceuticals ETF: Favorable Long-Term Growth Outlook Should Drive Future Price Appreciation
Stocks in IHE’s portfolio should benefit from rising global medicine demand.
Health Care Funds To Avoid
Recent comments by UnitedHealthcare highlighted the risk of health care reform.